CVS Health announced a new program to improve patient access to GLP-1 weight-loss medicines at its more than 9,000 U.S. pharmacies. The initiative offers virtual clinician visits for $49, with GLP-1 drugs priced as low as $25 per month for insured patients, $50 for eligible Medicare patients, or starting at $149 monthly for those without insurance, plus professional support and over-the-counter products to manage side effects. Bank of America analyst Allen Lutz raised his price target on CVS Health stock to $110 from $100 following the news, implying modest upside from the current price of about $104. The program could boost revenue in the company's retail pharmacy division and builds on recent financial improvements, including a 6% year-over-year revenue increase to $100.4 billion in the first quarter and a raised full-year 2026 guidance.
CVS Health CorpCVS launches GLP-1 access program across 9,000 pharmacies, potentially boosting retail pharmacy revenue.
Bank of America Corp